Natixis Advisors LLC Purchases 12,445 Shares of ResMed Inc. (NYSE:RMD)

Natixis Advisors LLC increased its holdings in shares of ResMed Inc. (NYSE:RMD) by 31.9% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned 51,498 shares of the medical equipment provider’s stock after purchasing an additional 12,445 shares during the period. Natixis Advisors LLC’s holdings in ResMed were worth $12,572,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Archer Investment Corp lifted its holdings in shares of ResMed by 5,159.1% during the third quarter. Archer Investment Corp now owns 1,157 shares of the medical equipment provider’s stock worth $282,000 after buying an additional 1,135 shares during the last quarter. Empowered Funds LLC increased its holdings in ResMed by 284.3% in the 3rd quarter. Empowered Funds LLC now owns 8,208 shares of the medical equipment provider’s stock valued at $2,004,000 after buying an additional 6,072 shares during the period. Empirical Finance LLC raised its position in ResMed by 2.0% in the third quarter. Empirical Finance LLC now owns 5,009 shares of the medical equipment provider’s stock worth $1,223,000 after purchasing an additional 99 shares in the last quarter. CIBC Asset Management Inc raised its holdings in shares of ResMed by 7.9% in the 3rd quarter. CIBC Asset Management Inc now owns 21,687 shares of the medical equipment provider’s stock worth $5,294,000 after buying an additional 1,581 shares in the last quarter. Finally, OneDigital Investment Advisors LLC increased its position in shares of ResMed by 4.1% during the 3rd quarter. OneDigital Investment Advisors LLC now owns 2,558 shares of the medical equipment provider’s stock worth $624,000 after purchasing an additional 100 shares in the last quarter. Institutional investors own 54.98% of the company’s stock.

Insider Buying and Selling at ResMed

In related news, CFO Brett Sandercock sold 1,000 shares of the stock in a transaction on Monday, September 9th. The shares were sold at an average price of $246.42, for a total transaction of $246,420.00. Following the completion of the transaction, the chief financial officer now owns 96,812 shares in the company, valued at approximately $23,856,413.04. This represents a 1.02 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Witte Jan De sold 796 shares of the firm’s stock in a transaction on Tuesday, November 12th. The shares were sold at an average price of $248.81, for a total transaction of $198,052.76. Following the completion of the transaction, the director now directly owns 6,723 shares of the company’s stock, valued at approximately $1,672,749.63. This trade represents a 10.59 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 62,174 shares of company stock valued at $14,882,278 in the last 90 days. 0.71% of the stock is currently owned by company insiders.

ResMed Trading Up 1.4 %

NYSE:RMD opened at $241.55 on Thursday. The company has a debt-to-equity ratio of 0.13, a current ratio of 2.92 and a quick ratio of 1.91. The business’s 50-day simple moving average is $242.10 and its 200-day simple moving average is $224.10. ResMed Inc. has a fifty-two week low of $150.39 and a fifty-two week high of $260.49. The stock has a market capitalization of $35.46 billion, a PE ratio of 31.99, a price-to-earnings-growth ratio of 1.71 and a beta of 0.69.

ResMed (NYSE:RMD) last announced its quarterly earnings results on Thursday, October 24th. The medical equipment provider reported $2.20 earnings per share for the quarter, beating analysts’ consensus estimates of $2.03 by $0.17. ResMed had a net margin of 23.15% and a return on equity of 25.53%. The firm had revenue of $1.22 billion for the quarter, compared to analyst estimates of $1.19 billion. During the same quarter in the previous year, the firm posted $1.64 earnings per share. The business’s revenue was up 11.1% on a year-over-year basis. Sell-side analysts expect that ResMed Inc. will post 9.28 earnings per share for the current fiscal year.

ResMed Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, December 12th. Shareholders of record on Thursday, November 7th will be issued a dividend of $0.53 per share. This represents a $2.12 dividend on an annualized basis and a yield of 0.88%. The ex-dividend date is Thursday, November 7th. ResMed’s dividend payout ratio (DPR) is presently 28.08%.

Analysts Set New Price Targets

Several brokerages have issued reports on RMD. Robert W. Baird lifted their price objective on ResMed from $280.00 to $283.00 and gave the company an “outperform” rating in a research report on Friday, October 25th. Wolfe Research reaffirmed an “underperform” rating and issued a $180.00 target price on shares of ResMed in a research note on Wednesday, September 18th. Baird R W raised shares of ResMed to a “strong-buy” rating in a research note on Tuesday, September 24th. StockNews.com raised shares of ResMed from a “hold” rating to a “buy” rating in a research note on Tuesday, October 15th. Finally, KeyCorp upped their price objective on ResMed from $251.00 to $266.00 and gave the company an “overweight” rating in a report on Friday, October 25th. One investment analyst has rated the stock with a sell rating, five have given a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $225.70.

About ResMed

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.